Tablets for oral administration comprise a) a first layer 1 that swells noticeably and rapidly on contact with aqueous biological fluids, the layer being prepared by compression of a mixture or granules having 5 - 90% by weight (pref. 10 - 85%) of hydrophilic polymers, b) a second layer 2 that is adjacent to or superposed on 1, containing alfuzosin hydrochloride (I), hydrophilic polymers, and auxiliary materials that give the mixture compressibility whilst allowing liberation of (I) over a predetermined period, and optionally c) a third layer 3 that is compressed and applied over 2 which is mainly hydrophilic polymers that gel and/or swell and which may erode, having the effect of modifying liberation of (I) from layer 2, this layer 3 being only slightly permeable to (I) these tablets giving controlled liberation of (I); at the proximal segments of the gastrointestinal tract (duodenum and jejunum).

Tablet with controlled release of alfusozin hydrochloride

MAGGI, LAURETTA;CONTE, UBALDO;
1996-01-01

Abstract

Tablets for oral administration comprise a) a first layer 1 that swells noticeably and rapidly on contact with aqueous biological fluids, the layer being prepared by compression of a mixture or granules having 5 - 90% by weight (pref. 10 - 85%) of hydrophilic polymers, b) a second layer 2 that is adjacent to or superposed on 1, containing alfuzosin hydrochloride (I), hydrophilic polymers, and auxiliary materials that give the mixture compressibility whilst allowing liberation of (I) over a predetermined period, and optionally c) a third layer 3 that is compressed and applied over 2 which is mainly hydrophilic polymers that gel and/or swell and which may erode, having the effect of modifying liberation of (I) from layer 2, this layer 3 being only slightly permeable to (I) these tablets giving controlled liberation of (I); at the proximal segments of the gastrointestinal tract (duodenum and jejunum).
1996
Chemistry & Analysis covers research on natural and laboratory syntheses, chemical structure, structure-function relationship, isolation and analyses of biologically significant molecules, medicinal and food chemistry. Technical material describing crucial chemical methods in biochemical analysis and research is also placed in this category. Resources covering general biochemistry and natural metabolic pathways are excluded.
EP938318B1
Maggi Lauretta
ELETTRONICO
Inglese
Internazionale
CONTROLLED RELEASE TABLET; ALFUZOSIN HYDROCHLORIDE; PHARMACEUTICAL TABLET
On this patent the following products were developped:Xatral® (alfuzosin 10 mg) OD (registered in more than 90 counties) and Uroxatral® in the US, a once-daily version of Sanofi-Aventis' Xatral®, a selective alpha-blocker for treating the urinary symptoms of benign prostatic hyperplasia. This patent is granted by the European Patent office and in the following countries: WO9808515 (A1) US6149940 (A) TR9900289 (T2) SK27099 (A3) SK284388 (B6) RU2183459 (C2) PT938318 (E) PL331862 (A1) PL191546 (B1) OA10983 (A) NZ334018 (A) NO990944 (A) NO326206 (B1) MXPA99001958 (A) KR20000035929 (A) JP2000514462 (A) IS4964 (A) IS2091 (B) IL128146 (A) HK1020875 (A1) GR3036291 (T3) ES2159400 (T3) EP0938318 (A1) EP0938318 (B1) EE9900090 (A) EE03855 (B1) DK938318 (T3) DE69704712 (T2) CZ9900655 (A3) CY2284 (B1) CO4920217 (A1) CN1543954 (A) CN100335057 (C) CN1228700 (A) CN1155382 (C) CA2264250 (A1) CA2264250 (C) BR9713237 (A) BR9713237 (B1) BG103138 (A) BG63768 (B1) AU4020197 (A) AU724490 (B2) AT200864 (T) AR009312 (A1) AP1107 (A)
6 Brevetti::6.1 Brevetto
none
Maggi, Lauretta; Conte, Ubaldo; Grenier, Pascal; Vergnault, Guy; Dofour, Alain; Jarreau Francois, Xavier; Rauch Desanti, Clemence
info:eu-repo/semantics/patent
285
7
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/202534
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact